SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported Binance security breach has fueled Bitcoin selling and weighed on MSTR, which traders view as a leveraged proxy for Bitcoin; the discussion also centers on Strategys Q3 revenue miss, earnings driven largely by Bitcoin valuation gains, and its CFO transition. Bears warn of further downside and dilution, while bulls characterize the drop as a buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid a reported major Binance security breach, with traders debating whether shaken confidence in exchanges and possible withdrawals could add selling pressure. Others argue Bitcoin has held up relatively well and view the decline as a buying opportunity, while the breachs broader impact remains uncertain.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Concern about the Nov. 30 IPO lockup expiration and potential insider selling is weighing on QNT, alongside a sharp selloff. Traders are split between expecting continued pressure and arguing that Quantinuums technical progress, Oracle partnership and federal funding support the longer-term case.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Third Quarter 2026 Financial ResultsPR NewswireWASHINGTON, Oct. 28, 2026 Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026Q3 2026 Total Operating...

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

Vanda Pharmaceuticals reports positive Phase 3 results for Nereus, demonstrating reduced vomiting linked to GLP-1 receptor agonist therapy.read more...

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced Vomiting

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced Vomiting Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS (tradipitant) for Prevention of GLP-1-Induced VomitingPR NewswireWASHINGTON, Oct. 27, 2026...

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026PR NewswireWASHINGTON, Oct. 21, 2026 Conference Call and Webcast to FollowWASHINGTON, Oct. 21, 2026 /PRNewswire...

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPR NewswireWASHINGTON, Oct. 14, 2026Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary...

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireWASHINGTON, Oct. 2, 2026WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the...

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

Equity

Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD).

$VNDA Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

Stocktwits

Vanda Pharmaceuticals Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.37 up 2.63% YoY
• Reported revenue of $1.61M down -97.14% YoY
• Vanda Pharmaceuticals expects full-year 2026 total revenue of greater than $240M; no quantified margin or earnings guidance was provided for full-year 2026 in the financial update.

Vanda Pharmaceuticals reported higher year-to-date net losses, cash decreased by $123.4M from December 31, 2025, and pending FDA-related court challenges involving HETLIOZ insomnia and NEREUS gastroparesis.

Vanda Pharmaceuticals reported Fanapt sales and prescription growth, positive Phase III results for NEREUS in GLP-1-associated vomiting, and BYSANTI approval with launch expected in Q4 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>In the trial, patients took 20 mg once daily for 28 days; treated patients fell asleep 42.5 minutes earlier versus 5.4 minutes on placebo — a 37-minute gap.</li><li>The “pivotal” trial analyzed just 20 patients per arm after screening more than 260 people over five years.</li><li>Investors also remember the FDA twice rejected Hetlioz for jet lag, citing how the studies were designed.</li></ul>Shares of Vanda Pharmaceuticals (<a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a>) opened 3% higher on Wednesday after a late Tuesday readout in delayed sleep-wake phase disorder, to eventually give up all gains as investors focused on the small trial population and generic competition to the drug.The stock was down 1% at the time of writing, despite a two-digit after-hours surge on Tuesday. &nbsp;<h2 class="st-heading-2">What The <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> Trial Showed</h2>Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD). In DSWPD, the internal clock is locked late: people cannot fall asleep at a normal hour and struggle to wake for work or school. The company estimates that 0.5 million to 4.1 million U.S. adults may be affected.In the trial, patients took 20 mg once daily for 28 days. Treated patients fell asleep 42.5 minutes earlier versus 5.4 minutes on placebo — a 37-minute gap. Sixty percent of the drug group advanced sleep by at least 30 minutes, versus 15% on placebo. Safety matched the existing label. Vanda plans to discuss the data with the U.S. Food and Drug Administration and file for a new use. If approved, Hetlioz would be the first medicine specifically cleared for DSWPD.<h2 class="st-heading-2">Why The Stock Did Not Rally</h2>The “pivotal” trial analyzed just 20 patients per arm after screening more than 260 people over five years. The main measure was a diary, not an objective sleep tracker. Investors also remember the FDA twice rejected Hetlioz for jet lag, citing how the studies were designed.Further, generic versions have already slashed Hetlioz sales — down 66% year over year to $5.6 million in the latest reported quarter. A new label on a product already facing cheap copies may add little revenue. Vanda is also burning cash while Fanapt, its approved drug for schizophrenia and acute manic or mixed episodes of bipolar I disorder, grows, and other pipeline bets remain unproven.Vanda is also awaiting an FDA decision on Quimilza in the treatment of generalized pustular psoriasis. The FDA is slated to decide on the drug by December 12.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$VNDA" data-symbol-id="VNDA" href="https://stocktwits.com/symbol/VNDA" target="_blank">VNDA</a> stock rose from bearish to extremely bullish territory over the past 24 hours, while message volume rose from normal to extremely high levels.A Stocktwits user highlighted that the company is currently unprofitable. The stock is doomed until it can turn a profit again, they said.<stembedurl>https://stocktwits.com/Ctres06/message/665434676</stembedurl>Another user highlighted the small nature of the study, which they said will not suffice for FDA approval.<stembedurl>https://stocktwits.com/Massimo21/message/665425060</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has fallen 43% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ai-labs-in-focus-us-ftc-reportedly-opens-probe-into-open-ai-anthropic-following-surge-in-rogue-ai-agents/cZMFhPuRBL7">AI Labs In Focus: US FTC Reportedly Opens Probe Into OpenAI, Anthropic Following Surge In Rogue AI Agents</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image: Colorful pills in glass bottles. Courtesy: Getty Images

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VNDA News